Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

Background Indications with poor T-cell infiltration or deficiencies in T-cell priming and associated unresponsiveness to established immunotherapies represent an unmet medical need in oncology. CD40-targeting therapies designed to enhance antigen presentation, generate new tumor-specific T cells, a...

Full description

Bibliographic Details
Main Authors: Malin Lindstedt, Peter Ellmark, Lennart Greiff, Karin Hägerbrand, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Rosén, Anette Sundstedt, Adnan Deronic, Lill Ljung, Mattias Levin, Laura Varas, Anna Säll, Christina Sakellariou, Barnabas Nyesiga, David Gomez Jimenez, Mona Celander, Deniz Bölükbas, Fredrika Carlsson
Format: Article
Language:English
Published: BMJ Publishing Group 2022-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/11/e005018.full

Internet

https://jitc.bmj.com/content/10/11/e005018.full

Similar Items